Actinic Prurigo
Actinic prurigo (AP), also known as Hutchinson's summer prurigo, is a chronic immune-mediated photodermatosis that runs a persistent course and can become severe. It usually begins in childhood (before age 10), affects girls and women more often, and is particularly common in Indigenous peoples of the Americas (Native American and Mestizo populations) as well as in some Asian populations.
Unlike polymorphic light eruption (PMLE), which is short-lived and tends to settle as the skin "hardens" to the sun, AP is a chronic, T-cell-mediated delayed hypersensitivity reaction under strong genetic control.
- Genetics and HLA Association:
- More than 80–90% of patients with AP carry HLA-DR4, especially the HLA-DRB1*0407 allele (predominant in Mestizo and Native American communities), or HLA-DRB1*0401/DRB1*0101 in White and Asian patients. This is a useful genetic marker that supports a definitive diagnosis.
- Cytokine-Driven Inflammation:
- Patients with AP show a sharp rise in proinflammatory cytokines, notably tumor necrosis factor-alpha (TNF-alpha), in both skin and serum. TNF-alpha is central to keeping the inflammation going: it drives infiltration by CD4+ T cells and the release of histamine from mast cells.
- Histopathology:
- Epidermis: Hyperkeratosis, spongiosis and acanthosis, distorted by chronic scratching.
- Dermis: The hallmark of AP is a dense perivascular lymphocytic infiltrate that organizes into TRUE LYMPHOID FOLLICLES with germinal centers. These are found in 60–70% of lip or skin biopsies from patients with AP and help clearly separate it from PMLE.
Actinic prurigo is among the photosensitive skin diseases with the greatest impact on quality of life. The itch is relentless, leading to scarred, thickened papules, changes to the lip mucosa and permanent scars. At Haute-Derma, our pathway of HLA-DRB1*0407 screening, lip biopsy to look for lymphoid follicles and TNF-alpha-targeted treatment (thalidomide or biologics) is the key to controlling steroid-resistant AP.
Clinical Features and Characteristic Sites
Whereas PMLE stays confined to sun-exposed skin, AP tends to spread to covered areas as well and is active all year round (worse in summer, but rarely clearing completely in winter).
Lesions on Exposed and Covered Skin
- Primary lesions: Scattered red papules and small vesicles that soon become firm, thickened, excoriated papules and nodules from intense scratching.
- Sun-exposed sites: Face (forehead, cheeks, bridge of the nose), ears, neck, V of the chest, forearms and backs of the hands.
- Covered sites (typical of AP): Itchy papules may also appear on the buttocks, thighs and back as a widespread id-like reaction.
Lip and Eye Involvement (Key Diagnostic Clues)
- Actinic cheilitis: Seen in 60–75% of patients (and may be the only sign in 10%). The lower lip is swollen, red and sore, with deep fissures and thick gray-brown crusts.
- Actinic conjunctivitis: Red eyes, photophobia, chronic tearing and papillary hypertrophy of the tarsal conjunctiva.
Differentiating Actinic Prurigo from Similar Conditions
| Actinic Prurigo (AP) | Polymorphic Light Eruption (PMLE) | Atopic Dermatitis / Other Prurigo |
|---|---|---|
| Childhood (<10 years) | Adulthood (20–40 years) | Childhood or older age |
| HLA-DR4 / DRB1*0407 positive (>80%) | No clear HLA association | Linked to IgE and the FLG gene |
| Lip involvement very common (60–75%) | Lip involvement very rare | Ordinary dry lips possible |
| NO hardening (sun exposure makes it worse) | Hardening occurs (improves by late summer) | No hardening |
| Dermal lymphoid follicles | Superficial dermal edema, perivascular lymphocytes | Hyperkeratosis, acanthosis, no lymphoid follicles |
Advanced Diagnosis and Treatment at Haute-Derma
At Haute-Derma, patients with AP are managed with a multi-target approach built around thalidomide and biologic therapy (the Haute-Derma AP Protocol):
Standard Diagnostic Workup
- Step 1: Dermoscopy of the papules and assessment of actinic cheilitis.
- Step 2: Molecular testing for the HLA-DRB1*0407 or DR4 allele.
- Step 3: A 3 mm punch biopsy of the lower lip mucosa or a skin papule to look for dermal lymphoid follicles.
Initial Symptom Control
- Potent topical corticosteroids: Clobetasol propionate 0.05% applied to itchy papules on the trunk once or twice daily for up to 14 days.
- Topical calcineurin inhibitors (TCIs): Tacrolimus 0.1% applied to the face and lips twice daily calms cheilitis safely without thinning the skin.
- H1 antihistamines: Used at 2–4 times the standard dose (e.g., fexofenadine).
Targeted Treatment: Thalidomide
- How it works: Thalidomide is a powerful TNF-alpha inhibitor that dampens the T-cell-mediated hypersensitivity reaction and can bring the itch under control within 1–2 weeks.
- Managing serious toxicity:
- Strictly contraindicated in pregnancy (causes severe birth defects).
- Electromyography (EMG) and nerve conduction testing every 3 months to detect peripheral neuropathy early. The drug is stopped immediately if numbness or tingling develops in the fingertips.
Alternative Biologic Therapy
- For patients who do not respond to, or cannot tolerate, thalidomide:
- TNF-alpha inhibitors: Infliximab or adalimumab has been reported to be effective in some cases.
- IL-4 receptor alpha antibody (dupilumab): Helps control chronic fibrotic prurigo and severe itch in AP with coexisting atopy.
